SCHEMBL5674319

SCHEMBL5674319

COc1ccc(S(=O)(=O)N2C(=O)C(O)(c3ccccc3Cl)c3cc(Cl)c(OC)cc32)c(OC)c1

nearest known ligand 0.45

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
AVPR1B P47901 18/20 0.45
AVPR1A P37288 6/20 0.45
OXTR P30559 6/20 0.45
AVPR2 P30518 2/20 0.45
GPR65 Q8IYL9 1/20 0.45
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5677741 0.90 AVPR1B (0.56) AVPR1BAVPR1AOXTRAVPR2GPR65
SCHEMBL5674060 0.87 AVPR1B (0.49) AVPR1BAVPR1AOXTRAVPR2GPR65
SCHEMBL5675395 0.83 AVPR1B (0.44) AVPR1BAVPR1AOXTRAVPR2GPR65
SCHEMBL1796340 0.83 AVPR1B (0.60) AVPR1BAVPR1AOXTRAVPR2GPR65
SCHEMBL5675651 0.82 AVPR1B (0.44) AVPR1BAVPR1AOXTRAVPR2GPR65
SCHEMBL5675252 0.80 AVPR1B (0.54) AVPR1BAVPR1AOXTRAVPR2GPR65
SCHEMBL5677829 0.78 AVPR1B (0.54) AVPR1BAVPR1AOXTRAVPR2GPR65
SCHEMBL5674460 0.78 AVPR1B (0.54) AVPR1BAVPR1AOXTRAVPR2GPR65
SCHEMBL5675622 0.78 AVPR1B (0.54) AVPR1BAVPR1AOXTRAVPR2GPR65
SCHEMBL5677783 0.78 AVPR1B (0.54) AVPR1BAVPR1AOXTRAVPR2GPR65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119086-B2 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use SANOFI-AVENTIS (FR) 2006-10-10 US disclosed
EP-1419150-B1 PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE SANOFI AVENTIS (FR) 2005-04-27 EP disclosed
US-20040180878-A1 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use SANOFI-AVENTIS (FR) 2004-09-16 US disclosed
EP-1419150-A2 PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE Sanofi-Aventis (FR) 2004-05-19 EP disclosed
WO-2003008407-A2 PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE SANOFI-SYNTHELABO (FR) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180878-A1 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use AVPR2, AVPR1A, AVPR1B AVPR1B 3/4885AVPR1A 2/4885OXTR 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.